Kennedy, Susan A.

Thumbnail Image
Preferred name
Kennedy, Susan A.
Official Name
Kennedy, Susan A.

Research Output

Filters

3
3
Reset filters

Settings

Now showing 1 - 3 of 3
  • Publication
    Vascular Endothelial Growth Factor (VEGF) Promotes Assembly of the p130Cas Interactome to Drive Endothelial Chemotactic Signaling and Angiogenesis
    (American Society for Biochemistry and Molecular Biology, 2016-12-22)
    Evans, Ian M. 
    ;
    Kennedy, Susan A. 
    ;
    Paliashvili, Ketevan 
    ;
    Santra, Tapesh 
    ;
    Kolch, Walter 
    ;
    et al. 
    p130Cas is a polyvalent adapter protein essential for cardiovascular development, and with a key role in cell movement. In order to identify the pathways by which p130Cas exerts its biological functions in endothelial cells we mapped the p130Cas interactome and its dynamic changes in response to VEGF using high-resolution mass spectrometry and reconstruction of protein interaction (PPI) networks with the aid of multiple PPI databases. VEGF enriched the p130Cas interactome in proteins involved in actin cytoskeletal dynamics and cell movement, including actin-binding proteins, small GTPases and regulators or binders of GTPases. Detailed studies showed that p130Cas association of the GTPase-binding scaffold protein, IQGAP1, plays a key role in VEGF chemotactic signaling, endothelial polarization, VEGF-induced cell migration, and endothelial tube formation. These findings indicate a cardinal role for assembly of the p130Cas interactome in mediating the cell migratory response to VEGF in angiogenesis, and provide a basis for further studies of p130Cas in cell movement.
      304Scopus© Citations 21
  • Publication
    ADAM10: a new player in breast cancer progression?
    (Cancer Research UK, 2015-08-18)
    Mullooly, Maeve 
    ;
    McGowan, Patricia M. 
    ;
    Kennedy, Susan A. 
    ;
    Duffy, Michael J. 
    ;
    et al. 
    Background: The ADAM proteases are best known for their role in shedding the extracellular domain of transmembrane proteins. Among the transmembrane proteins shed by ADAM10 are notch, HER2, E-cadherin, CD44, L1 and the EGFR ligands, EGF and betacellulin. As cleavage of several of these proteins has been implicated in cancer formation and progression, we hypothesised that ADAM10 is also involved in these processes. Methods: ADAM10 expression was decreased by RNA interference and the effects of this on cell numbers, invasion and migration were determined. We also examined the effect of ADAM10 inhibition on breast cancer cell line invasion and migration. Results: Using the triple-negative (TN) breast cancer cell lines, BT20, MDA-MB-231 and the non-TN cell line MDA-MB-453, knockdown of ADAM10 expression significantly decreased in vitro migration (Po0.01; for each cell line). Similarly, treatment with the ADAM10-selective inhibitor GI254023X reduced migration in the three cell lines (for BT20, Po0.001; for MDA-MB-231, P ¼ 0.005; for MDA-MB-453, P ¼ 0.023). In contrast, neither knockdown of ADAM10 nor treatment with the ADAM10-selective inhibitor GI254023X significantly affected cell numbers. Using extracts of primary breast cancers, higher levels of ADAM10 were found more frequently in high-grade vs low-grade tumours (Po0.001) and in oestrogen receptor (ER)-negative compared with ERpositive tumours (P ¼ 0.005). Analysis of pooled publicly available data sets found that high levels of ADAM10 mRNA were associated with adverse outcome in patients with the basal subtype of breast cancer. Conclusions: Based on our combined cell line and breast cancer extract data, we conclude that ADAM10 is likely to be involved in breast cancer progression, especially in the basal subtype.
      282Scopus© Citations 64
  • Publication
    Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS G13D
    (Springer, 2020-01-24)
    Kennedy, Susan A. 
    ;
    Jarboui, Mohamed-Ali 
    ;
    Srihari, Sriganesh 
    ;
    Raso, Cinzia 
    ;
    Charitou, Theodosia 
    ;
    Herrera-Montavez, Carlos 
    ;
    Krstic, Aleksandar 
    ;
    Matallanas, David 
    ;
    Kiel, Christina 
    ;
    Rauch, Nora 
    ;
    Rukhlenko, Oleksii S. 
    ;
    Kholodenko, Boris N. 
    ;
    Iglesias-Martinez, Luis F. 
    ;
    Ryan, Colm J. 
    ;
    Pilkington, Ruth 
    ;
    Kolch, Walter 
    ;
    et al. 
    Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but how oncogenic mutations impact these interactions and their functions at a network-level scale is poorly understood. Here, we analyze how a common oncogenic KRAS mutation (KRASG13D) affects PPIN structure and function of the Epidermal Growth Factor Receptor (EGFR) network in colorectal cancer (CRC) cells. Mapping >6000 PPIs shows that this network is extensively rewired in cells expressing transforming levels of KRASG13D (mtKRAS). The factors driving PPIN rewiring are multifactorial including changes in protein expression and phosphorylation. Mathematical modelling also suggests that the binding dynamics of low and high affinity KRAS interactors contribute to rewiring. PPIN rewiring substantially alters the composition of protein complexes, signal flow, transcriptional regulation, and cellular phenotype. These changes are validated by targeted and global experimental analysis. Importantly, genetic alterations in the most extensively rewired PPIN nodes occur frequently in CRC and are prognostic of poor patient outcomes.
      288